Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology

PURPOSE: GSK2982772 is a selective inhibitor of receptor-interacting protein kinase-1 (RIPK1) with a short 2- to 3-h half-life. In a previous modified-release (MR) study, a matrix monolithic formulation (80% GSK2982772 released over 12 h) provided a once-daily (QD) pharmacokinetic (PK) profile in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tompson, Debra, Whitaker, Mark, Pan, Rennan, Johnson, Geoffrey, Fuller, Teresa, Zann, Vanessa, McKenzie, Litza, Abbott-Banner, Kathy, Hawkins, Simon, Powell, Marcy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837545/
https://www.ncbi.nlm.nih.gov/pubmed/34988780
http://dx.doi.org/10.1007/s11095-021-03124-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837545/
https://www.ncbi.nlm.nih.gov/pubmed/34988780
http://dx.doi.org/10.1007/s11095-021-03124-7

Ejemplares similares